Every protocol below is reviewed by a SamaritanMD-licensed physician at your free consult, dispensed by a US-licensed 503A compounding pharmacy, and built into a Legacy coaching program — not bought off a checkout page. For each compound: what it addresses, how it works, and what to ask your physician about.
For people whose appetite, metabolism, or insulin signaling has stopped responding to lifestyle alone. The whole point of the Weight Loss program is doing this without losing the muscle that most telehealth clinics quietly let go.
Addresses: Appetite that won't quiet down, food noise, plateau-resistant weight, blood-sugar swings.
A GLP-1 receptor agonist — slows gastric emptying, reduces appetite signaling, and improves how the body handles glucose. The longest-tenured of the modern GLP-1s. STEP-1 trial averaged ~15% body weight loss at 68 weeks.
Addresses: Same as semaglutide, plus people who under-respond to single-agonist GLP-1s.
A dual GLP-1 + GIP receptor agonist. The added GIP arm appears to drive more pronounced fat-mass loss and metabolic benefit at the cost of comparable GI side effects. SURMOUNT-1 averaged ~21% body weight loss over 72 weeks.
Addresses: Largest tested weight-loss magnitudes. People who've already tried sema or tirzep and want the next-generation option.
A triple-receptor agonist — GLP-1 + GIP + glucagon. The glucagon arm adds an energy-expenditure component on top of appetite suppression. Phase 2 TRIUMPH trial: 12-mg arm averaged 24.2% body weight lost over 48 weeks. Phase 3 TRIUMPH-4 readouts began Dec 2025.
For people whose tendons, joints, and gut lining don't bounce back the way they used to. Recovery peptides only matter if there's a training load to recover from — your Legacy coach makes sure there is.
Addresses: Lingering tendon pain, tendinopathy, gut-lining issues, slow-healing soft-tissue injuries.
A short peptide originally derived from human gastric juice. Promotes fibroblast activity, modulates the nitric oxide system, and stimulates angiogenesis (new capillary growth) at injury sites. Strong preclinical evidence for tendon and ligament repair.
Addresses: Whole-body soft-tissue recovery, multi-site soreness, persistent inflammatory states.
Promotes actin polymerization, progenitor-cell recruitment, and cellular migration — the physical processes underneath wound healing. Unlike BPC-157, TB-500 circulates systemically, so it can support healing in multiple regions simultaneously. Phase I human safety data at 42–1,260 mg over 14 days showed no toxicity.
Addresses: Skin elasticity, hair density, scar remodeling, soft-tissue repair quality.
A naturally-occurring copper-binding tripeptide. Stimulates fibroblast proliferation, regulates matrix metalloproteinases, and supports collagen turnover. Levels of GHK-Cu in human plasma drop measurably with age, which is one reason it's prominent in skin/connective-tissue protocols.
Addresses: Gut inflammation, IBS-like symptoms, persistent low-grade inflammatory load.
A short anti-inflammatory peptide derived from alpha-MSH. Studied for gut-mucosa support and inflammatory pathway modulation. Often paired with BPC-157 + TB-500 (the "KLOW" healing stack).
Addresses: Same use cases as BPC-157, with profile differences your physician will explain.
A modified pentadecapeptide with arginate salt formulation. Designed to address some of the bioavailability and stability tradeoffs of the original BPC-157, while keeping the same broad tissue-repair action.
These don't supply growth hormone — they signal the pituitary to release more of your own. Studied for sleep depth, recovery, body composition, and the over-40 "I just don't bounce back" complaint.
Addresses: Light, broken sleep; flat recovery; gradual decline in IGF-1 with age.
A 29-amino-acid synthetic GHRH originally FDA-approved in the 1990s. Stimulates pituitary GH release in a pulsatile, physiologic pattern. Sermorelin remains explicitly compoundable in the current FDA framework — one of the few in the GH family that does.
Addresses: Recovery between hard training blocks, deeper sleep, body-composition stalls in lifters over 35.
CJC-1295 sustains GHRH signal for 9–11 days post-dose; Ipamorelin triggers selective GH release without significantly affecting cortisol or prolactin. Paired, they amplify both the duration and the spike of natural GH release. Subject to ongoing FDA reclassification.
Addresses: Stubborn visceral fat, body-comp goals over 40, IGF-1 optimization.
A GHRH analog with the strongest body-composition data in the GH family — Phase III trials with imaging endpoints documented visceral-fat reductions. The most clinically validated of the GHRH analogs we work with.
For people thinking in decades, not weeks. Longevity protocols are quieter than weight-loss protocols — you're not chasing a scale number, you're protecting capacity. The Health 60-Day program is built around this category.
Addresses: Disrupted circadian rhythm, age-related sleep changes, telomere/longevity goals.
A short synthetic peptide originally isolated from the pineal gland. The first peptide demonstrated to extend telomere length in laboratory studies. Animal longevity research has documented extended maximum lifespan in treated populations. Human applications remain experimental.
Addresses: Metabolic resilience, exercise capacity, cellular-energy decline that shows up as "I don't recover the way I used to."
A 16-AA peptide encoded inside the mitochondrial genome itself. Acts as a retrograde signal between mitochondria and the nucleus, regulating gene expression and metabolic homeostasis. Plasma MOTS-c levels decline measurably with age — restoring them in animal models reverses metabolic deficits.
Addresses: Cellular energy, mitochondrial function, "I'm exhausted at a level sleep doesn't fix."
A coenzyme central to cellular energy metabolism and DNA repair. Levels decline with age and metabolic stress. Studied for energy production, mitochondrial health, and longevity protocols.
For high-output professionals over 35 who notice the brain fog before they notice the gym slowdown. Studied for focus under load, calm under pressure, and stress modulation without the side effects of stimulants or benzodiazepines.
Addresses: Generalized stress, performance anxiety, mental fatigue, focus that fades by mid-afternoon.
An anxiolytic / nootropic peptide originally developed in Russian neuroscience programs. Studied for mood stabilization and stress modulation without sedation. Often used as a daily nasal spray rather than an injection.
Addresses: Cognitive load, focus, neuroprotection, recovery from cognitive stressors.
A short peptide derived from a fragment of adrenocorticotropic hormone. Studied for nootropic effects, neuroprotective signaling, and BDNF (brain-derived neurotrophic factor) modulation. Nasal-spray protocol; commonly stacked with Selank.
Addresses: Light sleep, fragmented sleep, the over-40 "I slept 8 hours and feel like 4."
A 9-AA peptide studied for slow-wave (deep) sleep architecture, recovery, and stress-response modulation.
Two pathways your physician will discuss: the melanocortin route (PT-141, central nervous system) and the PDE-5 route (sildenafil family, vascular). They work differently and address slightly different aspects of the experience.
Addresses: Libido (men & women), sexual responsiveness — the desire side, not the mechanical side.
Activates melanocortin receptors in the central nervous system. The mechanism is upstream of the vascular pathway — addresses desire and arousal directly rather than via blood-flow chemistry.
Addresses: ED — the mechanical side. Different molecules suit different timing preferences.
PDE-5 inhibitors that increase blood flow via the nitric-oxide / cGMP pathway. Sildenafil ~4-hour window, tadalafil up to ~36 hours, vardenafil similar onset to sildenafil with a slightly different side-effect profile.
For men over 35–40 whose energy, drive, and recovery are flatter than they used to be. Hormones are a signal — without a strength-training stimulus, the signal does nothing. Legacy coaching is the stimulus.
Addresses: Persistent fatigue, lower drive, slower recovery, declining body composition — the classic over-40 picture.
Restores serum testosterone toward optimal range when biochemically low. Drives mitochondrial biogenesis and protein synthesis — but the protein-synthesis benefit only matters if there's a training stimulus to direct it. Roughly 6–12% of men 40–49 are biochemically below 300 ng/dL.
Addresses: Men who want T optimization without exogenous testosterone or fertility shutdown.
A SERM that modulates estrogen feedback at the hypothalamus, prompting the body to produce more of its own testosterone. Used when fertility preservation matters, or as a step before considering TRT.
Addresses: HPTA support during TRT, fertility preservation, testicular function maintenance.
Mimics LH at the testes, maintaining endogenous function during exogenous testosterone administration. Common adjunct to a TRT protocol when fertility matters.
All compounds described above are prescribed only after evaluation by a SamaritanMD-licensed physician at intake and dispensed by a US-licensed 503A compounding pharmacy. Statements have not been evaluated by the FDA where applicable. Compounded GLP-1 medications (semaglutide, tirzepatide, retatrutide) are not FDA-approved drug products. Some compounded peptides are subject to ongoing FDA Pharmacy Compounding Advisory Committee review (PCAC; July 2026); prescribing eligibility depends on each substance's current 503A status. Nothing on this page is medical advice; final clinical decisions are made by your prescribing physician.
Tell your SamaritanMD physician your goals — they'll point you at the right protocol and tell you if a peptide isn't the right fit. The coaching plan that goes with it comes from your in-house Legacy coach.